Recently, Yunnan Baiyao Group Co.Ltd(000538) announced that the company held the third meeting of the ninth board of directors in 2022, deliberated and adopted the proposal on the appointment of senior managers of the company, and appointed Professor Zhang Ning as the chief scientist of Yunnan Baiyao Group Co.Ltd(000538) group.
The announcement shows that the competition of modern biomedical technology enterprises is essentially the competition of talents and innovation ability. Building a strong independent R & D capability and global resource integration capability based on an excellent talent team and driven by continuous innovation investment is the key to the sustainable development of Yunnan Baiyao Group Co.Ltd(000538) in the new era. Zhang Ning was appointed as the chief scientist to further enrich the R & D pipeline of Yunnan Baiyao Group Co.Ltd(000538) . While the company’s original R & D capacity of traditional Chinese medicine continues to improve, it builds an advanced R & D capacity of biological and chemical pharmaceutical products, focuses on user needs, integrates a variety of product forms and creates a comprehensive pharmaceutical solution.
Zhang Ning is a doctor and professor of Biochemistry, cell and molecular biology at Johns Hopkins University School of medicine. Currently, he is the deputy director of Peking University – Yunnan Baiyao Group Co.Ltd(000538) Xi’An International Medical Investment Company Limited(000516) Research Center, vice president of International Cancer Research Institute of Peking University, executive deputy director of tumor transformation research center of the first hospital of Peking University, vice president of Artificial Intelligence Research Institute of Peking University, vice president of International Research Institute of health big data of Peking University, and chief researcher of Cancer Hospital Research Institute of Tianjin Medical University. Zhang Ning has been engaged in biomedical and cell biology research for a long time. Focusing on the key clinical problem of cancer metastasis, he has carried out transformation application research from the aspects of mechanism research, biomarker identification, drug screening and so on, and achieved a series of major scientific research achievements.
